Introduction 64
Liposomal amphotericin B (AmBisome®; Gilead Sciences Europe Ltd) is a widely used 65
antifungal compound for the treatment of invasive fungal infections (9). This lipid formulation 66 consists of amphotericin B studded in the wall of a unilamellar liposome of approximately 80 nm in 67 diameter. A regimen of 3 mg/kg/day is effective for the treatment of invasive infections caused by 68
Candida spp. and Aspergillus spp. (7, 18) . Liposomal amphotericin B is also used for the treatment of 69 cryptococcocal meningitis and infections caused by the Mucorales (16, 19) . 70
Despite extensive clinical trial data that supports a regimen of 3 mg/kg/day, there is 71 increased interest in the use of alternative regimens. A longer dosing interval extends the utility of 72 liposomal amphotericin B to ambulatory settings, which may be especially useful in the setting of 73
prophylaxis (primary and secondary) and for consolidation therapy for infections where the use of 74 orally bioavailable compounds is precluded. At the present time, there is considerable uncertainty 75 regarding safe and effective intermittent regimens. Clinical studies that have been performed are 76 relatively small and have not been designed to detect differences in clinical outcomes (see for 77 example (6, 10)). Further clinical studies are currently being planned and conducted. 78
Here, we describe the population pharmacokinetics of liposomal amphotericin B. These 79 data were acquired as a component of a clinical study that compared a conventional (i.e. 80 3mg/kg/day) with an intermittent regimen (10 mg/kg on day 1, followed by 5 mg/kg at 48 and 120 81 hours) of liposomal amphotericin B for patients with profound and prolonged neutropenia with 82 fever that was refractory to broad spectrum antimicrobial agents. The clinical aspects of this study 83 have been previously reported (12). The current study reports the population pharmacokinetics of 84 liposomal amphotericin B in these patients and represents a first critical step for the future rational 85 design of intermittent regimens. Liposomal amphotericin B was measured in serum using high pressure liquid 122 chromatography (HPLC). A C18 5µ 50 x 20mm column (Agilent, Cheshire, UK ) was used. Active drug 123 was extracted with 300 µL methanol (Fisher, UK). The mobile phase was: (a) 0.1% aqueous formic 124 acid (Fisher, UK); and (b) 0.1% formic acid in acetonitrile (Fisher, UK). A gradient was used beginning 125 with A/B 80/20, increasing to 30/70 over 7 mins. was used. A flow of 0.8 mL/min was used. 126
Amphotericin B was measured using UV detection with emission 406 nm and excitation of 385 nm, 127 respectively. The internal standard was piroxicam in methanol (2 µg/mL). Serum concentrations 128 were estimated using a standard curve in the concentration range 0-100 mg/L. The injection volume 129 was 50 µL. The retention time for amphotericin B and the internal standard was 4.0 and 2.3 mins., 130
respectively. The limit of detection was 0.05 mg/L. The intra and inter-day variation in the assay 131 were both < 10%. 132
133

Population Pharmacokinetic Modeling 134
All data were modeled using a population methodology and with the pharmacokinetic 135 used. Subsequently, a three compartment model was also fitted. This model enabled the relatively 146 high peak concentrations and persistently detectable concentrations after cessation of dosing to be 147 better described. These two-and three-compartment models were compared and distinguished on 148 the basis of the observed-predicted values both before and after the Bayesian step, the coefficient 149 of determination of the linear regression of these data, the log likelihood value, a measure of bias 150 (mean weighted error), and precision (bias-adjusted weighted mean squared error). Statistically 151 significant differences in the log likelihood values were assessed by calculating twice the difference 152 were plotted (note: this is not the same as confidence intervals, which cannot be accurately 176 determined using a nonparametric approach). 177
178
Statistical Methods 179
The Bayesian estimates for volume and clearance for patients receiving intermittent versus 180 conventional daily regimen were plotted on a histogram and compared using the Mann-Whitney U 181 test with the statistical program SYSTAT 11. A linear regression of the Bayesian estimates for both 182 on August 29, 2017 by guest http://aac.asm.org/ Downloaded from volume and clearance against weight was performed. An assessment was made as to whether the 183 slope of the regression lines deviated in a statistically significant manner from zero was performed 184 using the statistical package SYSTAT 11. 185 186
Optimal Sampling Times 187
Optimal sampling times for both a conventional and intermittent regimen were estimated 188 using the SAMPLE module of ADAPT 5. An estimate of these times for the population was obtained 189 using the method originally described by Tam and Drusano (25) The mean concentration-time profiles for a patient weighing 68 kg (the mean weight of the 220 study population) and receiving a conventional and intermittent regimen is shown in Figure 3 in 221 panels A and B respectively. As is evident from Figure 3 
